Outlook Therapeutics Provides Detailed Update Following FDA Type A Meeting on ONS-5010/LYTENAVA™ (bevacizumab-vikg)

Key Highlights

• FDA Type A Meeting Held: Outlook Therapeutics (Nasdaq: OTLK) has provided a significant update after a Type A meeting with the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for ONS-5010/LYTENAVA™ (bevacizumab-vikg).
• Background: The meeting followed a Complete Response Letter (CRL) from the FDA dated December 30, 2025, which stated that more substantial evidence of effectiveness was needed before approval could be granted.
• Company’s Response: Outlook Therapeutics is actively engaging with the FDA to clarify outstanding issues, specifically regarding the confirmatory evidence of effectiveness required for approval.
• Regulatory Path Forward: Discussions are ongoing to achieve alignment with the FDA on the evidence needed and to determine the most efficient path to potential approval in the United States.
• Clinical Data: ONS-5010/LYTENAVA™ demonstrated “clinically meaningful and statistically significant improvements” in visual acuity in the pivotal NORSE TWO Phase 3 trial, meeting both primary and key secondary endpoints. Additional confirmatory evidence was provided by the NORSE EIGHT trial and other data included in the BLA.
• Safety: The product candidate has shown a favorable safety profile, with no safety concerns identified by the FDA to date.
• Market Potential: If approved, ONS-5010/LYTENAVA™ would be the first FDA-approved ophthalmic formulation of bevacizumab in the U.S., offering standardized manufacturing, FDA-approved labeling, and robust pharmacovigilance.
• Existing Approvals: The product (as bevacizumab gamma) already holds centralized Marketing Authorization from the European Commission and the UK’s MHRA for the treatment of wet AMD. Commercial launches have begun in Germany, Austria, and the UK.
• Supply Chain: ONS-5010/LYTENAVA™ is supported by a fully domestic, end-to-end U.S. manufacturing supply chain.

Details for Shareholders and Potential Price Sensitivity

• Regulatory Risk: The FDA’s current lack of acceptance regarding the sufficiency of evidence for effectiveness represents a pivotal risk. Any further delays or additional requirements could affect the timeline to market and impact share value.
• Potential First-Mover Advantage: Approval in the U.S. would make ONS-5010/LYTENAVA™ the first FDA-approved ophthalmic bevacizumab, potentially capturing a significant share of the retinal disease treatment market.
• Global Expansion: The company has already received marketing authorizations in Europe and the UK, and commercial launches are underway. U.S. approval would further expand its addressable market.
• Ongoing Engagement with FDA: The outcome of continued discussions and the company’s ability to meet FDA requirements could be a major catalyst for the stock, either positively (in case of progress/approval) or negatively (in case of further setbacks).
• Forward-Looking Statements: The company has reminded investors that all statements about future regulatory decisions, commercial prospects, and market conditions carry significant risks, including those related to additional regulatory hurdles, pharmaceutical development, macroeconomic trends, and global conflicts.

Product and Market Overview

ONS-5010/LYTENAVA™ (bevacizumab-vikg) is an ophthalmic formulation of bevacizumab developed for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases. The U.S. formulation is investigational and pending FDA approval, while the European and UK versions (bevacizumab gamma) have received marketing authorization for wet AMD.

The drug is a recombinant humanized monoclonal antibody that binds to all isoforms of VEGF, inhibiting their activity and thereby reducing abnormal blood vessel formation, leakage, and retinal damage.

If approved in the United States, ONS-5010/LYTENAVA™ would address a significant unmet need by providing a standardized, FDA-approved product for retinal indications, improving consistency and safety over off-label compounding practices.

Risks and Forward-Looking Statements

Investors should be aware that the regulatory process is ongoing and subject to change. Risks include the possibility of additional FDA requests, market adoption rates, and macroeconomic uncertainties such as overseas conflicts, inflation, and global supply chain issues.

The company’s ability to secure FDA approval and successfully commercialize ONS-5010/LYTENAVA™ in the U.S. remains a key variable for Outlook Therapeutics’ future value and share performance.

Investor Contact

For further information, investors can contact Jenene Thomas, Chief Executive Officer of JTC Team, LLC at 908.824.0775 or [email protected].

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from those anticipated. Investors should consult the company’s filings with the SEC and consider their own financial circumstances and risk tolerance before making any investment decisions.

View Outlook Therapeutics, Inc. Historical chart here